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SUMMARY
Background. A higher degree of mortality may be attributed to patients with epilepsy. There are several 
main reasons responsible – sudden unexpected death in epilepsy (SUDEP), status epilepticus (SE) and cen-
tral nervous system damage. Also, epilepsy associated accidents and suicidal attempts have to be high-
lighted.
Aim. Epidemiology and therapeutic or preventive (pharmacological or non-pharmacological strategies) 
of the conditions increasing mortality have been reviewed so as to minimize the mortality rate in patients 
with epilepsy.
Discussion and Conclusions. Generally, the treatment of convulsive SE entails the need to achieve rapid 
stabilization of a patient and an appropriate choice of antiepileptic drugs (AEDs) so as to stop seizure ac-
tivity. In the event of no response the treatment has to be continued under general anaesthesia. For min-
imizing the risk of SUDEP in young adults or patients with childhood epilepsy, adequate treatments with 
AEDs must be initiated or possible surgery considered. Patients with uncontrolled epilepsy require AED 
optimization. Although a possible link between taking AEDs and increased suicidality is questionable, pa-
tients with epilepsy are advised to be evaluated for possible symptoms of depression or anxiety. Surgical 
treatment of epilepsy may increase the risk of depression development, so a careful psychiatric examina-
tion is recommended prior to surgery.
Key words: status epilepticus • sudden • unexpected death in epilepsy • depression • suicide • injuries 
• epilepsy
BACKGROUND
Mortality in the cohort of epileptic patients is consid-
erably higher than in the general population. It is esti-
mated to be 1.6–11.4 times higher than in healthy peo-
ple and the ratio for epileptic children may be between 
5.3 and up to 9.0 times higher (Lathoo, Sander, 2005). 
The bigger risk of death in epileptic patients is attrib-
uted to a variety of factors, which may be classified into 
several types.
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Among the most frequently listed factors there is the 
course of the epilepsy underlying disease (damages of 
the central nervous system [CNS]), sudden unexpected 
death in epilepsy (SUDEP) and status epilepticus (SE). 
Other factors include seizure-resulting accidents (inju-
ries, drowning, burns, choking, aspiration pneumonia 
after seizures), suicidal attempts of epileptic patients or 
the adverse impact of pharmacotherapy (Lathoo, San-
der, 2005; Devinsky et al., 2016; Konopko, Rola, 2017).
Lathoo and Sander (2005) have proposed a classifi-
cation which includes the following categories: epilep-
sy-related deaths, underlying disease-related deaths 
and unrelated deaths. The first category, epilepsy-re-
lated deaths, involves directly related diseases, SUDEP, 
SE, accidents being the outcome of seizures, suicidal 
attempts of epileptic patients or the adverse impact of 
pharmacotherapy (drug toxicity or idiosyncratic reac-
tions to a treatment). The second category – underly-
ing disease-related deaths – comprises such causes as 
primary and secondary CNS neoplasia, cerebrovascu-
lar disease, CNS infection and inherited neurodegen-
erative disorders. Finally, there are epilepsy-unrelat-
ed deaths, which include non-CNS neoplasia, ischem-
ic heart disease, pneumonia and accidents unrelated to 
seizures (Lathoo, Sander, 2005; Devinsky et al., 2016).
DISCUSSION
Status epilepticus
Epidemiology of SE
Amare et al. (2008) have stated that the occurrence of 
SE reaches between 18 and 61 instances per 100,000 per 
year, with 70% of convulsive SE, secondary generalized 
CSE being more frequent than the primary generalized 
one. SE is the first symptom of epilepsy in approximate-
ly 10% of cases (Amare et al., 2008). Epileptic patients 
display a higher risk of SE when they withdraw from 
taking AEDs. Other contributing factors include ad-
ditional diseases or co-occurring metabolic dysfunc-
tions (Towne et al., 1994). The risk of the occurrence 
of SE in individuals who had not been identified as ep-
ileptics could be increased by structural brain distur-
bances, metabolic disorders as well as toxic substances 
and addictions (Lowenstein, 1999).
The frequency of SE is claimed to be 9.9 per year 
per 100 000 of the inhabitants of the French-speaking 
regions in Switzerland (Coyetaux et al., 2000), 13.1 – 
16.5 in Italy (Vignatelli et al., 2003; 2005), and 15.8 in 
Germany (Knake et al., 2001). Mortality as a result of SE 
has been determined to reach 20–40% and it depends 
on its cause, duration, patient’s age, co-occurring dis-
eases, etc. (Lowenstein, 1999).
Epileptic patients are clearly more prone to risk of 
death induced by SE, but some of them more than the 
others. The risk factors linked with higher probability 
of decease include old age, being male, prolonged SE, 
as well as acute symptomatic aetiology (nervous system 
infections, stroke or metabolic dysfunctions; Beghi et 
al., 2005; Devinsky et al., 2016). Lower mortality in SE 
is found with idiopathic etiology or AEDs withdrawal 
(Amare et al., 2008).
Propositions for a new definition of SE
One of the first definitions of the SE was presented in 
1876 by Trousseau, who wrote “In the SE when the con-
vulsive condition is almost continuous, something spe-
cial takes place which requires an explanation” (Trin-
ka et al., 2015).
In 1964, Gastaut and colleagues coined a more mod-
ern and precise definition of SE, described as a “seizure 
that persists for a sufficient length of time or is repeated 
frequently enough to produce a fixed or enduring epi-
leptic condition” (Trinka et al., 2015). SE is considered 
to take place if there were recurring seizures and a pa-
tient remains unconscious for 60 minutes between sei-
zures. A similar concept was proposed in 1983 by the 
International League Against Epilepsy (ILAE) and the 
World Federation of Neurology. More recent defini-
tions specify the seizure duration as 30 minutes (Trin-
ka et al., 2015). The most recent definition of SE, for-
mulated by Trinka et al. (2015), specifies time point t1 
and t2 and it describes SE as a disorder resulting from 
failure of mechanisms responsible for seizure termina-
tion or initiation of mechanisms leading to prolonged 
seizure duration beyond time point t1. Time point t1 
is an indicator of a period during which treatment of 
SE should be initiated, whereas time point t2 indicates 
the border after which there is a risk of long-term con-
sequences of SE. These consequences may include neu-
ronal death, neuronal injury or alteration of neuronal 
networks, depending upon the type and duration of 
seizures (Beghi et al., 2005).
The convulsive SE is considered to occur when a time 
point t1 is equal to 5 minutes, and t2 reaches 30 min-
utes. A focal SE with impaired consciousness is consid-
ered to occur if the time values for time points t1 and t2 
are 10 minutes and more than 60 minutes respective-
ly (Beghi et al., 2005). As highlighted previously, Trin-
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ka et al. (2015) developed a concept of two time points, 
t1 and t2. Those two points indicate at possible conse-
quences of the SE if their duration is exceeded. The time 
limits are varied for different types of SE. For the ton-
ic-clonic SE, the values of each time point is 5 and 30 
minutes respectively. In case of focal SE with impaired 
consciousness, the duration of t1 is 10 minutes, where-
as the value for t2 is longer than 60 minutes. As regards 
the absence SE, the value for the first time point is con-
sidered to be 5–10 minutes, and it is unknown for t2. 
However, the scientific evidence for the time frame is 
currently not sufficient and potential findings in the 
future may modify these current values.
Treatment of SE
Based on a variety of input data from patients’ obser-
vations, Trinka et al. (2015) postulate that treatment of 
convulsive seizures should begin within approximately 
5 minutes. Regardless of the above information, it must 
be stressed that time limits provided are constructed 
mainly for operational purposes only and the onset tim-
ing may vary significantly in different clinical circum-
stances (Lathoo, Sander, 2005; Devinsky et al., 2016). It 
is estimated that at least half of the patients with SE do 
not have epilepsy or do not demonstrate specific epi-
lepsy syndromes. A new classification of SE, proposed 
by Trinka et al. (2015) incorporates four underlying el-
ements: semiology, etiology, electro-encephalographic 
(EEG) correlates and age. These elements are consid-
ered to provide a framework so that it is possible to es-
tablish clinical diagnosis and carry out a specific ther-
apeutic approach for each patient (Trinka et al., 2015). 
The classification takes into account extremely impor-
tant non-convulsive SE. It is a descriptive term denot-
ing instances of SE with very little or no clinical signs 
of ongoing seizures except for obtundation or subtle 
motor phenomena (Kinney et al., 2017).
The primary goal of treating convulsive SE is quick 
termination of seizure activity, stabilization of a patient 
and instituting a proper anticonvulsive treatment to 
prevent pulmonary edema and arrhythmia (Stölberger, 
Finsterer, 2004; Jones et al., 2014). The variety of causes 
and symptoms in SE require a careful and complex pro-
cedure to design efficient treatment. Taking care of SE 
incorporates the treatment of early SE (according to the 
old definition, 30 minutes as of its onset), established SE 
(30 – 120 minutes as of the onset), refractory SE (more 
than 120 minutes) and super-refractory SE (exceeding 
24 hours; Trinka et al., 2015; Glauser et al., 2016).
Glauser et al. (2016) have developed and proposed an 
algorithm for treating SE at various stages, correspond-
ing to the time values presented above. According to 
the model, stage 1 is the treatment of the early SE. At 
this stage, it is recommended to administer benzodiaz-
epines (e.g. intravenously (IV) lorazepam, buccal mida-
zolam, IV or rectal diazepam). The second stage is the 
established SE. The recommended agents during this 
stage are IV AEDs – such as phenytoin, phenobarbital 
or valproate. If the SE continues and the patient does 
not respond to stage 1 and stage 2 treatments, then the 
advised course is to continue treatment under general 
anaesthesia (recommended agents include propofol, mi-
dazolam, thiopental/pentobarbital; Glauser et al., 2016).
A loading dose of valproate or levetiracetam may be 
administered IV. However, only 7% of patients who have 
not responded to timely and appropriate AED doses 
during previous stages will then respond to any AED 
during the third stage (Treiman et al., 1998). Third-line 
AEDs are used mainly to avoid intubation. Stage 4 oc-
curs when the SE continues or recurs for 24 hours or 
more even though a general therapy with anaesthesia 
had been utilized (Treiman et al., 1998).
Glauser et al. (2016) have developed and proposed 
the following protocol for treating SE. The first stage 
is called the Stabilization Phase and its duration is five 
minutes. The primary task during this stage is to sta-
bilize the patient, checking airways, breathing and cir-
culation function and perform neurological examina-
tion in order to identify any disability. While continu-
ing monitoring vital signs, assess patient’s oxygenation, 
providing oxygen by means of nasal mask. If respirato-
ry assistance is required, it might be necessary to utilize 
intubation. The following steps at this stage are initiat-
ing ECG monitoring and checking blood glucose level. 
If it is below 60 mg/dl, it is recommended to administer 
thiamine (adults 100 mg Iv, then 50 ml D50W IV; chil-
dren older than 2: 2ml/kg D25W IV, less than 2 years 
old: 4 mg/kg D12.5W). The final step is to try gaining 
IV access and check the level of electrolytes, haema-
tology, perform a toxicology screen and measure an-
ticonvulsant drug levels (Glauser et al., 2016). The fol-
lowing stage is called Initial Therapy Phase and it takes 
between 5 and 20 minutes from the onset. The recom-
mended course of action at this stage is administering 
benzodiazepines. If seizures do not stop, then the treat-
ment with recommended AEDs and dosages should be 
continued. Otherwise, if patient is at the baseline, then 
employing symptomatic medical care is recommended 
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(Glauser et al., 2016). The second stage therapy phase 
takes place during the 20–40-minute time bracket. 
However, during this phase, there is no preferred evi-
dence-based procedure. The recommended courses to 
be followed and agents to be administered to patients 
include fosphenytoin, valproate, levetiracetam (IV) or 
if these are not available, then IV phenobarbital should 
be used. Note, that only one second line option should 
be chosen and administered as a single dose (Glauser 
et al., 2016). The third stage therapy phase occurs be-
tween 40 and 60 minutes from SE onset. Again, at this 
stage, there are no evidence-based therapies to be rec-
ommended, but it is suggested to repeat the second line 
therapy with general anaesthetics (using thiopental, mi-
dazolam, pentobarbital or propofol). Also, EEG moni-
toring must be performed continuously. As in the above 
phases, if seizures do not stop, continue the therapy and 
if the patient is at the baseline, then employ sympto-
matic medical care (Glauser et al., 2016).
Other recommendations for treating SE in adult pa-
tients were proposed by Jones et al. (2014) in the In-Hos-
pital Emergency Drug Management of Convulsive SE 
in Adults. The first treatment step in the event of SE 
is administering benzodiazepines for longer than five 
minutes. The first-choice drugs at this stage are loraz-
epam (IV), diazepam (IV) or clonazepam (IV). If IV 
administration is not possible or difficult, then buc-
cal midazolam may be given (alternatively – injection 
through a buccal route or intramuscular injection). If 
the above methods are difficult or impossible then the 
alternative is administering diazepam rectally. Even if 
the seizures stop, the recurrence rate after this stage is 
relatively high. Therefore, it is recommended that most 
patients receive an IV stage 2 AED to prevent further 
seizures (Jones et al., 2014). The second step of the pro-
tocol proposed by Jones et al. (2014) should be imple-
mented when no response to Step 1 treatment is vis-
ible within 10 minutes. The recommended agents at 
this stage include one of the following: phenytoin, le-
vetiracetam, sodium valproate or phenobarbital. These 
agents should be considered as alternatives and admin-
istered intravenously (Jones et al., 2014). If phenyto-
in is given, patient should constantly have electrocar-
diogram (ECG) and blood pressure monitored due to 
a risk of hypotension and bradycardia. As regards sodi-
um valproate, it should be avoided in SE of an unknown 
cause in young patients. Also, caution is recommend-
ed for pregnant women or if patients suffer from acute 
liver failure. In such situations, alternative agents are 
recommended. In case of phenobarbital, it is extreme-
ly important to monitor blood pressure, ECG and res-
piratory function. The latter function is of paramount 
importance since phenobarbital may induce respirato-
ry depression. Therefore, it should be administered on-
ly if ventilator support is available. One of the require-
ments at this stage is informing a neurointensivist or 
experienced anaesthetist about the patient and his or 
her condition (Jones et al., 2014). Step 3 is implemented 
when there is no response to Step 2 within 30 minutes 
as of the onset. If patients are hemodynamically stable 
at that stage, it is recommended to optimize the dose of 
the initial second stage AED and consider administer-
ing an alternative second stage drug. Patients should re-
ceive anaesthesia (with intubation and ventilation) and 
be admitted to the intensive care unit. Also, like in the 
previous step, a neurointensivist or an experienced an-
esthetist should be made aware of the patient and his or 
her condition. During this stage, patients should be ad-
ministered propofol, thiopentone or midazolam (if pa-
tients are already ventilated; Jones et al., 2014).
The American Epilepsy Society recommends the fol-
lowing currently available AEDs to be used for treating 
convulsive SE in adult patients and in children during 
post-neonatal period. The first line AEDs to be used 
as primary agents include midazolam (IM), diazepam 
(IV) and lorazepam (IV), and if these are not possible 
to utilise, then alternatives are recommended: diaze-
pam (rectally), phenobarbital (IV), midazolam (buc-
cally) or midazolam (nasally). The second line AEDs 
include valproic acid (IV), levetiracetam (IV), pheny-
toin (IV), fosphenytoin (IV), as a primary choice. The 
alternatives comprise phenobarbital (IV) (Glauser et al., 
2016). As highlighted above, if SE lasts 120 minutes or 
longer, it is referred to as the refractory SE. This stage 
is assumed to occur in approximately 25–35% of epi-
leptic patients. In the event of refractory SE, the rec-
ommended protocol is either repeating the second-line 
therapy or administering general anaesthesia (recom-
mended agents include propofol, midazolam, thiopen-
tal/ pentobarbital). Patient must be EEG monitored at 
all times and the treatment should take place in an in-
tensive care unit (Glauser et al., 2016).
If the SE does not stop or recurs after 24 hours from 
onset, despite administering timely and appropriate 
doses of AEDs with general anaesthesia, it is referred 
to as the super-refractory SE. The options that may 
be employed as a part of therapy include enteral ad-
ministration of topiramate (up to 1600 mg/d), IV la-
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cosamide (200–600 mg), ketamine (0.9–3 mg/kg – 
0.3–7.5 mg/kg/h), or magnesium sulphate (IV, satura-
tion dose; 3–6 g). Other substances and methods that 
may be considered include corticosteroids (IVIG), plas-
mapheresis, but also ketogenic diet, VNS (Vagus Nerve 
Stimulation), ECT (Electroconvulsive therapy) and 
rTMS (Repetitive Transcranial Magnetic Stimulation; 
Glauser et al., 2016).
Sudden unexpected death in epilepsy (sudep)
Definition and criteria
The acronym SUDEP refers to the disorder known 
as Sudden Unexpected Death in Epilepsy, or “death 
in the shadows”, as some authors call it (Thom et al., 
2016; Shankar et al., 2017). Nashef et al. (2012) defined 
SUDEP as a sudden, unexpected death of an individ-
ual with recognized epilepsy. Death is not related to 
trauma or drowning, and it may be witnessed or not, 
also, it may be with or without evidence for a seizure 
(Nashef et al., 2012; Laxer et al., 2014). Annegers (1997) 
defined SUDEP by providing criteria for its identifica-
tion. SUDEP may be recognized if the victim had ep-
ilepsy, understood as recurrent unprovoked seizures. 
The second criterion of possible SUDEP is when the pa-
tients are dying unexpectedly even though their health 
condition could be described as reasonable. Another 
distinguishing factor is when the patient died sudden-
ly and also when death occurred during normal life ac-
tivities and regular circumstances. A strong prerequi-
site for possible SUDEP identification is a lack of ob-
vious medical causes of death. Based on the above cri-
teria, SUDEP has been classified into the following 
types. When all the above criteria have been met and 
confirmed in a post-mortem medical examination, it 
may be described as a definite SUDEP. Probable SUDEP 
also meets those criteria but it lacks sufficient medical 
post-mortem evidence. SUDEP is considered possible 
when the circumstances as to the patient’s death are 
unclear and could have been caused by other factors. 
Finally, SUDEP is regarded unlikely when the cause of 
death has been clearly determined or the circumstanc-
es indicate that the cause of death could not have been 
SUDEP (Annegers, 1997; Bell, Sander, 2006). Nashef 
et al. (2012) also distinguished the category of Defi-
nite SUDEP plus and the Experienced SUDEP whilst 
Shankar et al. (2017) are of the opinion that there are 
even more categories of this particular condition.
SUDEP epidemiology
The estimated occurrence of SUDEP in the overall pop-
ulation of epileptic patients, expressed as a ratio, ac-
counts for 0.58 per 1000 patient-years (the ratio may 
range within 95% confidence intervals: 0.31 and 1.08). 
The incidence ratio in childhood patients is assessed 
to be 0.22 per 1000 patient-years (the range may vary 
between 0.16 and 0.31), whereas in adult patients it is 
1.2 (0.64–2.32). Based on the findings, it may be con-
sidered that SUDEP is the cause of death in 8–17% of 
patients with epilepsy (Hesdorffer et al., 2011; Hard-
en et al., 2017).
Hypotheses on the SUDEP pathomechanism
The literature presents various hypotheses regard-
ing the pathomechanisms of SUDEP, defining them 
as underlying causes of the disorder. However, it must 
be stressed that current knowledge of pathophysiolo-
gy and underlying neurobiology is insufficient, and 
these hypotheses may, and probably will, be subject to 
change in the future.
One of the possible pathomechanisms of SUDEP is 
the Central Sleep Apnoea, being the result of seizure 
activity propagation onto the respiratory centre and its 
blockage with secondary hypoxia (Walczak, 2003; So, 
2006; Richerson et al., 2016). Another mechanism is the 
impairment of the respiratory ducts patency as a result 
of larynx spasm with secondary asphyxia (Hesdorffer, 
Tomson, 2013; Kennedy et al., 2015). It is also suggest-
ed that SUDEP may be caused by neurogenic pulmo-
nary oedema, which is the result of severe α adrenergic 
response, generalized contraction of pulmonary ves-
sel and increased pulmonary pressure (Leestma et al., 
1997; Walczak, 2003).
SUDEP may also be induced by cardiac rhythm dis-
orders, mainly tachyarrhythmia and bradyarrhythmia, 
which are caused by dysfunction of the autonomous 
nervous system. There is evidence which indicates that 
SUDEP may overlap with sudden cardiac death or sud-
den infant death syndrome. An important thing to re-
member is the fact that life-threatening cardiac disor-
ders can demonstrate in a very similar manner to ep-
ilepsy (Walczak, 2003; Lee, Devinsky, 2005; Lamberts 
et al., 2012; Goldman et al., 2016). It is often recom-
mended that in case of epileptic patients a cardiac his-
tory and ECG should be obtained and the family history 
of sudden or unexpected deaths should be investigated 
(Nousiainen et al., 1989; Bergfeldt, 2003; Lee, Devinsky, 
2005; Lamberts et al., 2012). One of the possible patho-
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mechanisms of SUDEP is suboptimal AED concentra-
tions or rapid withdrawal of AEDs. Similar effect may 
be caused by some AEDs, especially those modifying 
the action of sodium channels, which affect the func-
tions of the autonomous nervous system (Nousiainen 
et al., 1989; Bergfeldt, 2003; Lee, Devinsky, 2005; Lam-
berts et al., 2012). Some authors also indicate at genet-
ic predispositions, especially those linked with muta-
tions in the genes responsible for developing the long 
QT syndrome (Konopko, Rola, 2017). Certain findings 
reveal that mutations in genetic epilepsies may increase 
predisposition to sudden death and susceptibility in ac-
quired epilepsies (Konopko, Rola, 2017).
Apart from SUDEP pathomechanisms, there are 
also risk factors which are hypothesized to increase 
the probability of the SUDEP occurrence. There are 
the following risk factors that seem to foster SUDEP: 
male, young age (less than 45), long time (chronic) ep-
ilepsy (15–30 years), early onset of a disease, insuffi-
cient treatment history, epilepsy with tonic-clonic sei-
zure, night time seizures, high frequency of epileptic 
seizures, multiple drug therapy and frequent changes 
of pharmacotherapy, excessive use of alcohol, frontal 
lobe epilepsy, mental dysfunctions, co-occurring anx-
iety and depression disorders, and using lamotrigine 
(women in particular) (Tomson, 2000; Tomson et al., 
2005; Hesdorffer, Tomson, 2013; Tomson et al., 2013; 
Holst et al., 2013; Granbichler et al., 2015; Tomson et 
al., 2016). According to Walczak (2003), the results of 
most studies have not revealed a relationship between 
any AED and SUDEP. There are, however, suggestions 
that carbamazepine may be a risk factor due to its as-
sociation with arrhythmia or disturbed cardiac auto-
nomic function (Walczak, 2003).
Potential strategies for preventing SUDEP in high-risk 
patients
As highlighted above, the various factors could indi-
cate a higher probability of SUDEP occurrence. There-
fore, it is advisable to develop strategies that will pro-
vide the optimum results should a specific risk factor 
or potentially terminal circumstances occur (Kiani 
et al., 2014). For young adults suffering from epilepsy 
or for individuals with childhood epilepsy onset, it is 
advisable to provide immediate medical and surgical 
treatment that will minimize the risk of SUDEP (Bell, 
Sander, 2006; Johnston, Smith, 2007). For patients suf-
fering from uncontrolled epilepsy or those displaying 
generalized tonic-clonic seizures the advisable strate-
gy is AED optimization. It may also be recommend-
ed to consider epilepsy surgery. In case of suboptimal 
AED concentrations, the recommended course is im-
proving drug compliance and providing patient su-
pervision. The recommended strategy for patients tak-
ing multiple AEDs is decreasing AED administration, 
whereas frequent changes/adjustments in pharmaco-
therapy may require regimen stabilization. As regards 
other risk factors, the abuse of alcohol (or other sub-
stances) may require abstention (if possible), whereas 
the recommended strategy for mental disorders or re-
tardation is increased supervision (Ryvlin et al., 2011; 
2013; Maguire et al., 2016).
In case of potentially terminal events, the strategies 
aim at reducing the impact of a given event and pre-
vent patient’s death. Therefore, a recommended strate-
gy for seizure occurrence is increased supervision and 
seizure alarm; pulmonary oedema should be identified 
and treated; the strategy for apnea or hypoxia is moni-
toring of pulse oximetry as well as stimulation and oxy-
genation (Hirsch, 2009; Nashef, Richardson, 2016). Car-
diac monitor and pacemaker are recommended if asys-
tole occurs and the strategy for suffocation is chang-
ing the environment in which the patient is currently 
placed or changing patient’s location (Klenerman et al., 
1993; Rugg-Gun et al., 2016).
Discussing the issue of SUDEP with epilepsy patients
Despite its extremely significant impact upon patients’ 
well-being and a potentially lethal outcome, physicians 
rarely discuss SUDEP with their patients. According to 
some authors, only 2.7% of neurologists and child neu-
rologists in Austria, Germany and Switzerland address 
this issue with their patients (Strzelczyk et al., 2016). On 
the other hand, 92.9% of neurologists pass on the infor-
mation that operating mechanical vehicles is prohibited 
and 81.5% pass on information regarding the everyday 
problems and limitations experienced and faced by ep-
ileptic patients (Kroner et al., 2014; Miller et al., 2014; 
Strzelczyk et al., 2016).
Donner et al. (2016) present the outcome of a survey 
carried out in a group of British physicians in 2006. The 
results indicate that only 4.7% of them highlight the is-
sue of SUDEP to all patients, whereas 25.6% discuss it 
with the majority of patients and 7.6% never bring it 
to the attention of anyone. In 2015, 20% of physicians 
were noted to pass important information to all fami-
lies, whereas 7% never brought it to the attention of any 
patient (Donner et al., 2015).
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Suicides
The problem of suicide is extremely urgent in the pop-
ulation of epileptic patients. It is estimated that suicidal 
thoughts are twice as frequent in epileptics as in gener-
al population, with 12% found in epileptic children and 
20% in adolescents. When compared with the gener-
al population, other suicide-related symptoms are also 
higher in epileptic patients. It has been reported that su-
icidal attempts were more frequent by 4.6–30%, where-
as actually committed suicides were more frequent by 
2.3–14%. The mortality rate as a result of suicidal at-
tempts is ten times higher than in the general popula-
tion. This value is even larger in case of frontal lobe ep-
ilepsy patients, with a staggering 25 times higher val-
ue (Bell, Sander, 2009; Hesdorffer, Kanner, 2009; Bell 
et al., 2009; Greydanus et al., 2010; Bagary, 2011; Mula, 
Sander, 2013; Mula et al., 2013).
Between 2003 and 2011, an analysis was carried 
out of the suicidal incidents among epileptic patients 
in 17 US states. The annual suicide ratio amounted to 
16.89/100,000, and the risk of committing suicide in 
this group was 22% higher than in general population, 
in particular in the 40–49 age bracket – suicides com-
mitted by poisoning (Tian et al., 2016).
Risk factors of suicide in epileptic patients
It is possible to identify a variety of general and epilep-
sy-specific factors which frequently occur in suicide 
attempts. The general ones include the sense of soli-
tude, suicidal attempts in close family or friends, sui-
cidal thoughts and mental disorders. The epilepsy-spe-
cific risk factors linked with suicide comprise such as-
pects as stigmatization and discrimination, but also 
taking medicines which may induce depression effects 
as well as easy access to a large number of toxic drugs 
(Grabowska-Grzyb, 2005; Ferrer et al., 2014).
Is there an association between taking AEDs and the 
suicide rate?
The issue of increased suicidality induced by AEDs still 
triggers controversies and requires further investiga-
tion. In 2008, an alert was issued by the U.S Food and 
Drug Administration (FDA) about the increased risk 
of committing suicides for 11 AEDs after conducting 
199 clinical trials. Actually, “an increased risk of sui-
cidal thoughts and behaviors (suicidality)” was postu-
lated in patients prescribed AEDs. The FDA postulat-
ed a warning to be placed on the labels. In the end, it 
has not been introduced due to insufficient data, an ex-
tremely heterogeneous nature of risk linked with dif-
ferent AEDs and positive effects of the drugs offset-
ting rather minor adversities and potential suicidality 
(Mula, 2018). It was recommended, however, that epi-
leptic patients undergo a routine evaluation for symp-
toms of depression or anxiety that may eventually lead 
to a suicide (Maguire et al., 2014).
Undoubtedly, the FDA alert stimulated attempts to 
evaluate the possible relationship between taking AEDs 
and suicidal ideation – the number of publications on 
this issue has sharply increased, starting from 2008 
(Mula, 2018). Also, drug companies are interested in 
gathering the respective data from clinical trials with 
the use of AEDs. Among an e increasing number of cli-
nicians, this problem seems to be adequately considered 
although still many of them do not properly screen pa-
tients with epilepsy for the occurrence of depression or 
possible suicidal thoughts (Mula, 2018).
Epilepsy and depression – epidemiology
The higher probability of epileptic patients developing 
depression is a well-grounded fact, proven by the fol-
lowing data. Depression occurs in 9–37% of epileptic 
patients compared to 9–10% of individuals with other 
diseases and 6–19% of the general population, as indi-
cated by the studies carried out in Canada, the US and 
the UK. Similar studies in South Korea reveal a ratio 
of 27.8% in epileptic patients vs 8.8% in healthy pop-
ulation. Depression is almost six times more likely in 
the cohort of epileptic patients with frequent seizures 
than in those in remission (33% vs 6% respectively). It 
occurs more often in patients with poor seizure control 
compared to patients that are well-controlled (54.3% vs 
23.8% respectively). There is also a contrast between 
epileptic individuals with well controlled epilepsy and 
healthy population – approximately 14% of the former 
may experience depression compared to 8.8% in the 
latter group (Kwon, Park, 2014).
Depression and anxiety in people with epilepsy
As highlighted above, epileptic patients are significant-
ly more likely to experience depression than the gen-
eral healthy population. There are numerous risk fac-
tors that are found in epileptics which may be associ-
ated with potential occurrence of depression. These in-
clude complex partial seizures, large frequency of sei-
zures, seizure focus in the temporal lobe of a brain’s 
dominating hemisphere, use of barbiturates and ben-
zodiazepines or the condition of seizure–free patients 
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after temporal lobe resection. Interestingly, risk fac-
tors need not be of a medical or health-related nature. 
Depression and anxiety could be triggered and inten-
sified as a result of social isolation/exclusion (Grabow-
ska-Grzyb, 2005).
Patients with epilepsy who undergo surgical treat-
ment are susceptible to a higher risk of developing de-
pression. The treatment may lead to a depression or 
anxiety in one out of 2–3 patients (up to 30%) (Kanner, 
Balabanov, 2008). Personality disorders and psychoses 
are less frequent (Koch-Stoecker, 2002). It is therefore 
recommended to carry out a scrupulous psychiatric ex-
amination before the procedure so that such risks could 
be eliminated or minimized.
Injuries and body damage
Epilepsy patients are more prone to experiencing in-
juries, with a probability ratio estimated to be on av-
erage 3.42 (2.5–4.69) higher than in the general pop-
ulation. The most susceptible patients are those with 
generalised tonic-clonic seizures as well as those with 
poorly controlled seizures (Ficker, 2000; Asadi-Pooya 
et al., 2012; Sajjan et al., 2016).
After a 24-year observation, it was found that 1 out of 
10 children with epilepsy experienced serious injuries 
as a result of seizures. The majority of injuries occurred 
in the patients with frequent seizures. Therefore, it may 
be emphasised that the best way to prevent injuries is 
to ensure better seizure control (Forsgren et al., 2005; 
Wirrell, 2006; Beghi, 2009; Camfield, Camfield, 2015).
While analysing different types of injury, it becomes 
evident that patients with epilepsy demonstrate a high-
er probability of experiencing almost all types of in-
jury compared to the control group. Expressed as to-
tal values, both groups present a relatively low risk of 
having burns (4.5% in epileptic patients vs 1.4% in the 
control group), fractures (5.3% vs 2.8%), head injury 
(1.9% vs 0.7%) and dental injuries (4.5% vs 1.7%). The 
differences and total values are significant in soft tis-
sue injuries, with 43.6% of epileptic patients and 10% 
in the control group exposed to the risk. Interestingly, 
the individuals from the control group are more likely 
to be involved in car accidents when compared to ep-
ileptic patients (1% vs 0.4% respectively), but this may 
be the result of driving restrictions introduced for ep-
ileptic patients (Tomson et al., 2004; Tellez-Zenteno et 
al., 2010; Asadi-Pooya et al., 2012).
Preventing injuries in patients with epilepsy may 
not always be easy, but there are certain guidelines 
that could be applied, depending on patients’ lifestyle 
and everyday activities. Some procedures for all pa-
tients include aggressive treatment of epilepsy, mini-
mization of drug-related ataxia, but also regular phys-
ical activity in order to maintain bone mass or swim-
ming in the presence of another person. For higher risk 
patients, the preventive measures include bathing un-
der supervision, avoiding hot objects so as to prevent 
burns, wearing helmets (for some patients) and avoid-
ing high places (Spitz, 1998; Ficker, 2000; Nei, Bagla, 
2007; Gayatri et al., 2010).
CONCLUSIONS
Epilepsy-related deaths comprise cases of SUDEP, SE, 
suicides and accidents associated with seizure activi-
ty. In order to reduce the possibility of SUDEP, the oc-
currence of generalized tonic-clonic seizures must be 
reduced because these seizures are the main risk for 
SUDEP. According to Harden et al. (2017), a reduction in 
the risk of SUDEP may be treated as an additional ben-
efit to other obvious benefits. Considering that noctur-
nal seizures associated with postictal respiratory depres-
sion may also result in SUDEP, a presence of a bedroom 
observer would be recommended (Harden et al., 2017).
It is remarkable that the number of patients with-
out epilepsy, in whom SE may occur, is close to 50%. 
As a serious life-threatening condition, the treatment 
of SE must begin as soon as possible, and the main goal 
of treatment is aimed on the cassation of seizure activ-
ity. In the early stage of SE, benzodiazepines (prefera-
bly intravenously) are recommended and if the seizure 
activity does not stop then, in the next stage, IV phe-
nytoin, phenobarbital or valproate may be adminis-
tered. General anaesthesia may be required if the above 
treatments fail.
Although a possible association between taking some 
AEDs and committing suicides has been postulated, 
this negative relationship has not been proven. Never-
theless, patients with epilepsy require continuous mon-
itoring for the occurrence of depression or suicidal ide-
ation. One has to consider that these patients have been 
found particularly prone to depression and suicide and 
serotonin reuptake inhibitors may be considered for the 
treatment of depression in such patients (Błaszczyk, 
Czuczwar, 2016). Usually, these drugs do not lower the 
convulsive threshold and some of them may even ele-
vate this parameter (Błaszczyk, Czuczwar, 2016).
Epilepsy may be well controlled in the majority of 
epileptic patients, and apart from certain disease-relat-
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ed inconveniences, these people can have normal lives. 
However, epilepsy can show a different and more dan-
gerous face, which can bring a significant risk to pa-
tients and lead to their death. The particularly danger-
ous disorders are SE, SUDEP or higher risk of suicides.
It is extremely important to promote awareness of 
such risks and develop knowledge of the symptoms, and 
identification and proper procedures if they occur. It is 
not an exaggeration to claim that such knowledge and 
procedures can save many lives.
The problem of AED misuse may significantly in-
terfere with the issues discussed in this review. Usual-
ly, drug misuse in patients with epilepsy may be relat-
ed to irregular AED consumption, omissions of sin-
gle doses and even self-dependent changes in the daily 
drug load which may be elevated or reduced. Notewor-
thy, the fraction of non-complainant patients rang-
es from 20 to even 80%, the most frequently encoun-
tered type of misuse being drug omissions (Piskorska 
et al., 2013). Evidently, this particular problem seems 
responsible for the significant increases in seizure fre-
quency or AED toxicity, eventually leading to an ele-
vated probability of life-threatening conditions. Wors-
ened quality of life or poor professional or educational 
performance may further provoke untoward ideation 
in patients with epilepsy. Evidently, good compliance 
means that the possibility of life-threatening events will 
be considerably reduced.
Osteoporotic patients with epilepsy may pose a com-
plex clinical problem as mostly endangered with serious 
pathological fractures and some AEDs may actually be 
responsible for the reduction of bone mineral density. 
In particular enzyme inducing AEDs have been well 
documented in this respect. On the other hand, lam-
otrigine, and to a lower degree – levetiracetam, seem 
one of the most recommended AEDs to patients with 
epilepsy facing the problem of osteoporosis (Miziak et 
al., 2016). It is quite obvious that tailoring AEDs show-
ing the best protective activity against a given type(s) of 
seizures and lowest adverse potential is not always pos-
sible. Therefore, in patients with ongoing osteoporosis 
and prescribed hepatic enzyme inducing AEDs (car-
bamazepine, phenobarbital or phenytoin), preventing 
measures are recommended (treatment with bisphos-
phonates). Possibly, bisphosphonates can also be used 
in patients with epilepsy in whom osteoporosis is di-
agnosed (Miziak et al., 2016).
Although there are many antidepressant drugs which 
can be safely administered to patients with epilepsy 
with depression, there are some antidepressants, iden-
tified pre-clinically, as potentially hazardous to this pa-
tient population with similar clinical data on this is-
sue. These antidepressants include bupropion, clomi-
pramine and maprotiline and their use in patients with 
epilepsy should be discouraged (Banach et al., 2016). 
The probability of pharmacokinetic interactions be-
tween AEDs and antidepressant drugs need to be con-
sidered. Although some combinations of these drugs 
display such interactions, dose adjustments may be 
only necessary on an individual basis. However, drug 
monitoring may prove inevitable when the combined 
treatment with AEDs and antidepressants leads to an 
increase in seizure frequency or evident drug toxicity. 
On this basis, dose adjustments may be implemented 
(Banach et al., 2016).
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